CNCE Projected Dividend Yield
Concert Pharmaceuticals Inc ( NASDAQ : CNCE )Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 inhibitor that Co. discovered through the application of its DCE Platform® (deuterated chemical entity platform). Co. is evaluating CTP-543 in a Phase 3 clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition to its wholly-owned development programs, Co. has entered into collaborative arrangements with companies to develop deuterium-modified versions of their marketed products. 20 YEAR PERFORMANCE RESULTS |
CNCE Dividend History Detail CNCE Dividend News CNCE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |